Market Research Logo

Global Lysosomal Storage Disease (LSD) Market (Fabry, Gaucher & Pompe): Industry Analysis & Outlook (2018-2022)

Global Lysosomal Storage Disease (LSD) Market (Fabry, Gaucher & Pompe): Industry Analysis & Outlook (2018-2022)

Lysosomal Storage Disease (LSD) is a genetic disorder that causes various types of nervous system disorders such as clinical abnormalities and cellular dysfunction. There are more than 65 categories of LSD. This disease can be classified into Lipid Metabolism Disorder and Glycoprotein Metabolism Disorder. Further Lipid Metabolism Disorder is categorized into Gaucher disease & Fabry disease and Glycoprotein Metabolism Disorder into Pompe disease. LSD develops mainly due to deficiency of lysosomal enzyme in the living body. A person suffering from LSD could experience problems like abnormal growth of bones, delay movement of body, deafness, blindness, dementia, respiratory problems, fatigue/weakness, bone & joint deformity, organ enlargement, lung dysfunction, severe & fatal physical & mental health deterioration.

The global LSD market is expected to grow with growing Ashkenazi (Eastern and Western Europe) population, increasing pharmaceutical R&D spending, growing disposable income, rising healthcare expenditure and accelerating economic growth. Key trends of this rare disease market includes progressing drugs under pipeline and increasing preference towards gene therapy. However, there are some factors which can hinder growth of the market including stringent regulations and limited access to patent rights.

The report “Global Lysosomal Storage Disease (LSD) Market (Fabry, Gaucher & Pompe): Industry Analysis & Outlook (2018-2022)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook.

The report discusses the major growth drivers, key tends & developments and challenges of the market, covering the global market. The report profiles the key players of the market including Pfizer Inc., Sanofi S.A., Shire Plc and Protalix BioTherapeutics, Inc.


1. Market Overview
1.1 Lysosomal Storage Disease (LSD)
1.2 Classification of LSD
Table 1: Classification of Lysosomal Storage Disease (LSD)
Table 2: Categories of Gaucher Disease by Clinical Types
1.3 Symptoms
1.4 Diagnosis
1.5 Treatment
1.6 Upcoming Treatment
2. Global LSD Market Analysis
2.1 Global LSD Market Forecast by Value
Table 3: Global LSD Market Forecast by Value (2017-2022)
2.2 Global LSD Market Value by Category
Table 4: Global LSD Market Value by Category (2017)
2.3 Global Fabry Disease Market Forecast by Value
Table 5: Global Fabry Disease Market Forecast by Value (2017-2022)
2.4 Global Fabry Disease Market Value by Drugs
Table 6: Global Fabry Disease Market Value by Drugs (2017)
2.4.1 Global Fabrazyme Sales Value
Table 7: Global Fabrazyme Sales Value (2017-2022)
2.4.2 Global Replagal Sales Value
Table 8: Global Replagal Sales Value (2017-2022)
2.4.3 Global Galafold Sales Value
Table 9: Global Galafold Sales Value (2017-2022)
2.5 Global Gaucher Disease Market Forecast by Value
Table 10: Global Gaucher Disease Market Forecast by Value (2017-2022)
2.6 Global Gaucher Disease Market Value by Drugs
Table 11: Global Gaucher Disease Market Value by Drugs (2017)
2.6.1 Global Cerezyme Sales Value
Table 12: Global Cerezyme Sales Value (2017-2022)
2.6.2 Global Vipriv Sales Value
Table 13: Global Vipriv Sales Value (2017-2022)
2.6.3 Global Cerdelga Sales Value
Table 14: Global Cerdelga Sales Value (2017-2022)
2.7 Global Pompe Disease Market Forecast by Value
Table 15: Global Pompe Disease Market Forecast by Value (2017-2022)
2.8 Global Pompe Disease Market Value by Drugs
2.8.1 Global Myozyme Sales Value
Table 16: Global Myozyme Sales Value (2017-2022)
3. Market Dynamics
3.1 Growth Drivers
3.1.1 Growing Ashkenazi (Eastern and Western Europe) Population
Table 17: Ashkenazi (Eastern and Western Europe) Population (2013-2017)
3.1.2 Rising Pharmaceutical R&D Spending
Table 18: Global Pharmaceutical R&D Spending (2013-2017)
3.1.3 Increasing Disposable Income
Table 19: Global Gross National Income (GNI) Per Capita (2013-2017)
3.1.4 Growing Healthcare Expenditure
Table 20: Global Healthcare Expenditure (2013-2017)
3.1.5 Accelerating Economic Growth
Table 21: Global GDP Per Capita (2013-2017)
3.2 Key Trends & Developments
3.2.1 Progressing Drugs under Pipeline
Table 22: Drugs under Development for Lysosomal Storage Disease (2017)
3.2.2 Increasing Preference towards Gene Therapy
3.3 Challenges
3.3.1 Stringent Regulations
3.3.2 Limited Access to Patent Rights
4. Competitive Landscape
4.1 Global Market
4.1.1 Revenue Comparison of Key Players
Table 23: Global LSD Market Key Players - Revenue Comparison (2017)
4.1.2 Market Cap Comparison of Key Players
Table 24: Global LSD Market Key Players - Market Cap Comparison 4.1.3 Global LSD Market-Annual Treatment Cost Comparison by Company Table 25: Global LSD Market-Annual Treatment Cost Comparison by Company (2017)
5. Company Profiles
5.1 Pfizer Inc.
5.1.1 Business Overview
Table 26: Pfizer Inc. Revenues by Business Segments (2017)
5.1.2 Financial Overview
Table 27: Pfizer Inc. Revenues and Net Income (2013-2017)
5.1.3 Business Strategies
Table 28: Pfizer Inc. Significant Agreements (2017/2018)
Table 29: Pfizer Inc. Research and Development Expenditures (2015-2017)
5.2 Sanofi S.A.
5.2.1 Business Overview
Table 30: Sanofi S.A. Net Sales by Business Segments (2017)
5.2.2 Financial Overview
Table 31: Sanofi S.A. Net Sales and Net Income (2013-2017)
5.2.3 Business Strategies
Table 32: Sanofi S.A. Significant Acquisitions (2017/2018)
Table 33: Sanofi S.A. Research and Development Expenditure (2015-2017)
5.3 Shire Plc
5.3.1 Business Overview
Table 34: Shire Plc. Revenues by Therapeutic Areas (2017)
5.3.2 Financial Overview
Table 35: Shire Plc Revenues and Net Income (2013-2017)
5.3.3 Business Strategies
Table 36: Shire Plc Research and Development Expenditures (2015-2017)
Table 37: Shire Plc Advertising and Promotion Expenditure (2015-2017)
5.4 Protalix BioTherapeutics, Inc.
5.4.1 Business Overview
Table 38: Protalix BioTherapeutics, Inc. Product Pipeline (2017)
5.4.2 Financial Overview
Table 39: Protalix BioTherapeutics, Inc. Revenues and Net Income (Loss) (2013-2017) 5.4.3 Business Strategies
Table 40: Protalix BioTherapeutics, Inc. Research and Development Expenditures (2015-2017)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report